Hemodialysis patients with hyperphosphatemia
Conditions
Interventions
Lanthanum carbonate 250-750mg will be administered orally three times daily after meals for 5 years.
Sponsors
Phosphate Research group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) CKD5D patients undergoing HemoDialysis, Age >=20 2) Patients who can receive La carbonate treatment 3) Patients who undergo hemodialysis between 3 months and 10 years 4) Possible long term observation patients 5) Patients with written IC (Informed Consent)
Exclusion criteria
Exclusion criteria: 1) Patients with cancer or suspicious for cancer 2) Pregnant or possibly pregnant patients, patients on lactation 3) Patients who meet the contraindiation criteria in package insert of Lanthanum carbonate 4) Inappropriate patients for this study according to the investigator's judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| #Treatment status of phosphate binders and VitaminD #Measure aortic calcification (ACI) at baseline and after the treatment of La carbonate (maximum 5 years). | — |
Secondary
| Measure | Time frame |
|---|---|
| P,Ca, intact-PTH, Alb, Lipid, CRP, hepatic function, CTR, nPCR, vital sign, safety and tolerability at baseline and after the treatment of La carbonate (maximum 5 years). | — |
Countries
Japan
Contacts
Public ContactAssociate Professor, Shigeo Negi
Wakayama Medical University Division of Nephrology & Blood Purification Medicine
Outcome results
None listed